



AUG 13 2002

PATENT & TRADEMARK OFFICE

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
ATTY. DOCKET NO.
1662/49603U.S. SERIAL NO.
09/939,406APPLICANT
DOLITZKY et al.FILING DATE
August 24, 2001GROUP
5473**RECEIVED**

AUG 19 2002

TECH CENTER 1600/2900

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*
FB	2,830,056	April 8, 1958	RUSCHIIG et al.	—	—	
FB	2,891,063	June 16, 1959	SOMMEKES	—	→	
FB	2,507,408	May 9, 1950	JACOB	—	—	
FB	3,663,548	May 16, 1972	NITTA et al	—	—	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

* Copy of reference is not enclosed because reference is cited in Search Report (copy of reference provided by International Searching Authority).

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
FB	DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Forderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. 1584167 XP002196248 1-p-Toluolsulfonyl-2, 4-dimethyl-piperazine * abstract* & CHEM PHARM BULL, vol. 17, no. 1, 1969, page 94ff, NISHIMURA .
FB	FUJIMURA ET AL: "Synthesis, Structure and quantitative Structure-Activity Relationships of sigma receptor Ligands, 1- '2-(3,4-Dimethoxyphenyl)ethyl !-4-(3-phenylpropyl)piperazines" BIOORGANIC & MEDICINAL CHEMISTRY, vol. 5, no. 8, 1997, pages 1675-1683, XP002196245 Reaction of 4 and 5 on *page 1676*.
FB	CHEMICAL ABSTRACTS, vol. 71, no. 21, 24 November 1969 (1969-11-24) Columbus, Ohio, US; abstract no. 101885, NITTA, YOSHIHIRO ET AL: "Piperazine derivatives and their salts" XP002196247 *abstract* & JP 44 018306 B (CHUGAI PHARMACEUTICAL CO., LTD.) 11 August 1969 (1969-08-11).

EXAMINER <i>FBernhard</i>	DATE CONSIDERED <i>12/26/02</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	